Project Grant R21CA313161
Award Date 6/1/26
Completion Date 5/31/28
Dollars Obligated $483K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98105, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...
- Federal Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $456,414 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2025, through April 30, 2030. This award supports the clinical development and evaluation of B7-H3 Chimeric Antigen Receptor (CAR) T cell therapy for children and young adults with Diffuse Intrinsic Pontine Glioma (DIPG), a fatal...
- Federal Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $636,097 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded May 1, 2026, with an ultimate completion date of April 30, 2031. The research focuses on investigating the role of menin as a master regulator of Ewing sarcoma (EWS) cell stemness and plasticity, with the goal of developing novel treatment...
- Federal Grant Award Summary Seattle Children's Research Institute received a $470,759 Project Grant from the National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) effective September 1, 2025 through August 31, 2027. The award supports development of an innovative CAR-T (Chimeric Antigen Receptor T-cell) immunotherapy platform designed to overcome T-cell exhaustion in solid tumor treatment, specifically targeting hepatocellular carcinoma patients. The research deliverables...
- Federal Grant Award Summary The National Cancer Institute awarded Children's Research Institute a Project Grant of $467,968 under the Cancer Treatment Research program (CFDA 93.395) to conduct research evaluating the synergistic therapeutic effects of retinoic acid and proteasome inhibitors in neuroblastoma treatment. The grant period runs from June 1, 2026 through May 31, 2028. The primary deliverable is a systematic evaluation of combination therapy approaches using three proteasome inhibitors...
- Federal Grant Award Summary The National Cancer Institute awarded The Children's Hospital of Philadelphia Research Institute a $457,683 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2028. This research initiative focuses on developing and optimizing macromolecular prodrug-based drug delivery systems to enhance the efficacy of SN-38 (a topoisomerase I inhibitor) against high-risk neuroblastoma, the most common and deadly solid...
- Grant Award Summary Seattle Children's Research Institute received a $434,361 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025 through August 31, 2027. The award supports the development of a multispecific T cell engaging (MTE) therapy targeting mixed-phenotype acute leukemia (MPAL), a high-risk leukemia subtype that presents with both myeloid and lymphoid surface antigens. The research aims to...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $767,328 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025 through July 31, 2030. The award funds research to investigate targeting splicing vulnerabilities in neuroblastoma, a malignancy responsible for 15% of childhood cancer-related deaths. The research will evaluate the efficacy and mechanisms of indisulam, a molecular glue...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $683,698 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026 through May 31, 2031. The award supports research to develop and validate a novel therapeutic strategy for treating high-risk B-cell acute lymphoblastic leukemia (B-ALL), particularly in relapsed/refractory cases and those resistant to anti-CD19 therapy. The primary...